Work

1023P Long-term follow up of patients treated with a DNA vaccine (pTVG-HP) for PSA-recurrent prostate cancer

Year: 2024

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.1082

Authors: D.G. McNeel, T.P. Tonelli, L.E. Johnson, J. Eickhoff, G. Liu

Institutions: University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Exelixis, Incyte, European Commission, Eisai, Syöpäsäätiö, Servier, Ipsen

OpenAlex ID: W4402561364

FWCI:

Cites:

Cited by:

Related to: 10